April 2, 2021 — Gene expression biomarkers can help predict clinical outcomes in response to treatment with pathway-targeting therapeutics, thereby helping to identify patient subgroups likely to respond.
In a collaboration with investigators at Isofol Medical AB, the QuartzBio team analyzed the correlation between expression of folate pathway genes and clinical outcomes in response to a combination therapy targeting this pathway in metastatic colorectal cancer, as part of a Phase III clinical trial.
They identified potential prognostic markers with clinical benefit, and presented the results at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).
